PE20160687A1 - Analogos de heteroaril indol biciclico utiles como moduladores de ror - Google Patents

Analogos de heteroaril indol biciclico utiles como moduladores de ror

Info

Publication number
PE20160687A1
PE20160687A1 PE2016000783A PE2016000783A PE20160687A1 PE 20160687 A1 PE20160687 A1 PE 20160687A1 PE 2016000783 A PE2016000783 A PE 2016000783A PE 2016000783 A PE2016000783 A PE 2016000783A PE 20160687 A1 PE20160687 A1 PE 20160687A1
Authority
PE
Peru
Prior art keywords
bicycle
analogs useful
modulators
ror modulators
rorty
Prior art date
Application number
PE2016000783A
Other languages
English (en)
Inventor
Malini Bajpai
Sachin Sundarlal Chaudhari
Sanjib Das
Vishal Govindrao Deshmukh
Prashant Dilip Wadekar
Shailesh Ramesh Pardeshi
Daisy Manish Shah
Abraham Thomas
Neelima Khairatkar-Joshi
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of PE20160687A1 publication Critical patent/PE20160687A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)

Abstract

La presente invencion se refiere a compuestos de formula (I) y sales farmaceuticamente aceptables de los mismos, en la cual X, X1 es N o CH, M es -O- o -CO-, R2, R3 y R4 son entre otros halogeno, R5 es H o alquilo C1-C4, m es 0 a 3, n es 0 a 3, y p es 0 a 4, los cuales son activos como moduladores del receptor gamma t huerfano (RORyt) relacionado con retinoides. Estos compuestos previenen, inhiben, o suprimen la accion de RORty y por lo tanto son utiles en el tratamiento de enfermedades, trastornos, sindromes o afecciones mediados por RORty tales como, por ejemplo: dolor, inflamacion, COPD, asma, artritis reumatoide, colitis, esclerosis multiple, enfermedades neurodegenerativas y cancer
PE2016000783A 2013-12-10 2014-12-09 Analogos de heteroaril indol biciclico utiles como moduladores de ror PE20160687A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3853MU2013 2013-12-10
IN527MU2014 2014-02-14
IN2172MU2014 2014-07-04

Publications (1)

Publication Number Publication Date
PE20160687A1 true PE20160687A1 (es) 2016-08-11

Family

ID=52355020

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000783A PE20160687A1 (es) 2013-12-10 2014-12-09 Analogos de heteroaril indol biciclico utiles como moduladores de ror

Country Status (18)

Country Link
US (1) US9682977B2 (es)
EP (1) EP3080090B1 (es)
JP (1) JP2016539989A (es)
CN (1) CN105980364A (es)
AP (1) AP2016009281A0 (es)
AU (1) AU2014363035A1 (es)
BR (1) BR112016013425A2 (es)
CA (1) CA2933003A1 (es)
CL (1) CL2016001441A1 (es)
EA (1) EA029489B1 (es)
IL (1) IL246123A0 (es)
MX (1) MX2016007604A (es)
PE (1) PE20160687A1 (es)
PH (1) PH12016501105A1 (es)
SG (1) SG11201604714SA (es)
TW (1) TW201605797A (es)
WO (1) WO2015087234A1 (es)
ZA (1) ZA201604454B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201419015D0 (en) 2014-10-24 2014-12-10 Orca Pharmaceuticals Ltd Compounds
US10221142B2 (en) 2015-02-11 2019-03-05 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof
WO2017051319A1 (en) * 2015-09-21 2017-03-30 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl ether compounds as ror gamma modulators
US10344000B2 (en) 2015-10-27 2019-07-09 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
MX2018005004A (es) 2015-10-27 2018-09-12 Merck Sharp & Dohme Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
EP3368535B1 (en) 2015-10-27 2020-12-02 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
UY37507A (es) 2016-12-05 2018-06-29 Lead Pharma Holding Bv Moduladores de ror gamma (ror¿)
TW201906816A (zh) * 2017-07-06 2019-02-16 大陸商江蘇恆瑞醫藥股份有限公司 吲哚甲醯胺類衍生物、其製備方法及其在醫藥上的應用
CN110945002B (zh) * 2017-08-01 2021-12-24 正大天晴药业集团股份有限公司 作为RORγ抑制剂的双环化合物
WO2019100106A1 (en) * 2017-11-24 2019-05-31 The University Of Sydney Antibacterial compounds and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200621237A (en) * 2004-11-01 2006-07-01 Wyeth Corp [(1-h-indazol-3-yl)methyl]phenols and (hydroxyphenyl)(1h-indazol-3-yl)methanones
US7781479B2 (en) 2005-01-14 2010-08-24 Dainippon Sumitomo Pharma Co., Ltd. Heteroaryl derivatives
ES2646834T3 (es) * 2010-08-20 2017-12-18 Amira Pharmaceuticals, Inc. Inhibidores de autotaxina y usos de los mismos
WO2012028100A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
EP2638014B1 (en) 2010-11-08 2017-01-04 Lycera Corporation N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of ror-gamma activity and the treatment of diseases
WO2012100732A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof
WO2012100734A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Compounds useful as retinoid-related orphan receptor gamma modulators
EP2487159A1 (en) * 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
EP2511263A1 (en) 2011-04-14 2012-10-17 Phenex Pharmaceuticals AG Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
WO2013171729A2 (en) 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator

Also Published As

Publication number Publication date
EP3080090B1 (en) 2018-01-31
US9682977B2 (en) 2017-06-20
ZA201604454B (en) 2017-11-29
SG11201604714SA (en) 2016-07-28
CL2016001441A1 (es) 2017-03-03
JP2016539989A (ja) 2016-12-22
MX2016007604A (es) 2017-02-28
AU2014363035A1 (en) 2016-06-30
CN105980364A (zh) 2016-09-28
EA201691002A1 (ru) 2016-12-30
PH12016501105A1 (en) 2016-07-11
BR112016013425A2 (pt) 2017-08-08
US20160326163A1 (en) 2016-11-10
EA029489B1 (ru) 2018-04-30
AP2016009281A0 (en) 2016-06-30
TW201605797A (zh) 2016-02-16
EP3080090A1 (en) 2016-10-19
WO2015087234A1 (en) 2015-06-18
CA2933003A1 (en) 2015-06-18
IL246123A0 (en) 2016-08-02

Similar Documents

Publication Publication Date Title
PE20160687A1 (es) Analogos de heteroaril indol biciclico utiles como moduladores de ror
CL2018000289A1 (es) Compuestos nuevos como moduladores de ror gamma.
PH12016502045A1 (en) Aryl and heteroaryl ether compounds as ror gamma modulators
CO2017011093A2 (es) Derivados de 6,7-dihidropirido [2,1-a]isoquinolin-2-ona como antagonistas del receptor gpr84, y composiciones que los contienen
CO2018002060A2 (es) Compuestos farmacéuticos
CU24487B1 (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores de gamma ror
SV2016005311A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
CL2017002799A1 (es) Sulfonas triciclicas como moduladores del receptor huérfano relacionado con retinoide gamma (rory)
DOP2014000244A (es) Compuestos novedosos
PE20151144A1 (es) Moduladores de la orphan receptor gamma retinoides relacionados (ror - gamma) para uso en el tratamiento de las enfermedades autoinmunes e inflamatorias
CO7280468A2 (es) Antagonistas del receptor de 5-ht3
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
UY36708A (es) MODULADORES DE ROR GAMMA (RORy)
EA201591815A1 (ru) Бицикло [2.2.2] кислоты - модуляторы gpr120
PE20171649A1 (es) ALCOHOLES TRIFLUOROMETILICOS COMO MODULADORES DE ROR(gamma)T
EA201700042A1 (ru) Соединения имидазопиридазина
ECSP20024651A (es) Derivados de imidazol condensados sustituidos por grupos de hidroxilo terciario como inhibidores de gamma pi3k-y
UY35158A (es) ?moduladores selectivos del receptor de andrógenos novedosos?.
EA201792594A1 (ru) Положительные аллостерические модуляторы мусаринового рецептора м1
EA201600394A1 (ru) Трициклические соединения пиперидина
PE20181328A1 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
CL2018000504A1 (es) Compuestos carbociclicos novedosos como moduladores gamma ror.
AR098679A1 (es) COMPUESTOS DE HETEROARILO BICÍCLICO COMO MODULADORES DE RORg
CR20170140A (es) Compuestos de sulfonamida heterocíclica sustituída útiles como moduladores del canal del receptor de potencial transitorio a1 (trpa1)
CU20100124A7 (es) 3-hidroxipiridinas sustituidas y composiciones farmacéuticas de las mismas

Legal Events

Date Code Title Description
FD Application declared void or lapsed